<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929847</url>
  </required_header>
  <id_info>
    <org_study_id>2021/060</org_study_id>
    <nct_id>NCT04929847</nct_id>
  </id_info>
  <brief_title>Novel Skin Care for Chemotherapy- Related Dermatologic Toxicities</brief_title>
  <acronym>ChemoSkin</acronym>
  <official_title>Evaluation of a Novel Skin Care Product for the Management of Chemotherapy- Related Dermatologic Toxicities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jessa Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Notwithstanding the continuous progress in cancer treatment, patients with cancer still have&#xD;
      to cope with quality of life (QoL) - impairing complications. Especially an extensive&#xD;
      spectrum of dermatologic toxicities has been associated with cancer treatments. The number&#xD;
      and type of cutaneous toxicities have evolved over the past 50 years, paralleling the&#xD;
      development of new chemotherapeutic agents. The chemotherapy-related skin toxicities can&#xD;
      significantly impede the patient's emotional, physical, social, and financial well-being&#xD;
      resulting in a poor QoL. In rare cases of severe cutaneous reactions, treatment modifications&#xD;
      are needed, resulting in a diminished overall survival.&#xD;
&#xD;
      Important organizations in the field of oncology and supportive care, such as the MASCC, the&#xD;
      ASCO, and the ESMO, have developed guidelines for the management of cancer therapy- related&#xD;
      cutaneous toxicities based on available scientific evidence. Still, for some interventions,&#xD;
      the evidence of recommendation is moderate to insufficient. Therefore, it is essential to&#xD;
      elucidate other new potential management strategies for dermatological complications of&#xD;
      cancer treatment. Based on the previously mentioned supportive care guidelines for the&#xD;
      ChemoSkin project, a novel emollient to tackle the cutaneous adverse events of chemotherapy&#xD;
      has been developed.&#xD;
&#xD;
      The ChemoSkin project general aim is to evaluate the efficacy of a novel skincare product to&#xD;
      manage chemotherapy-related cutaneous toxicities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective Evaluate the efficacy of a novel emollient for the management of&#xD;
      chemotherapy-related cutaneous adverse events&#xD;
&#xD;
      Secondary objective 1 Evaluate patient-relevant treatment benefit of the novel emollient for&#xD;
      chemotherapy-associated cutaneous toxicities&#xD;
&#xD;
      Secondary objective 2 Evaluate the influence of the novel emollient for chemotherapy-&#xD;
      associated cutaneous toxicities on the patient's quality of life&#xD;
&#xD;
      Secondary objective 3 Evaluate the safety of the novel emollient for chemotherapy- associated&#xD;
      cutaneous toxicities&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Baseline</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 1 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 2 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 3 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 4 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 5 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 6 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 7 of chemotherapy (washout)</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 8 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 9 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 10 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 11 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 12 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>Week 13 of chemotherapy</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin reaction evaluation</measure>
    <time_frame>2 weeks post-chemotherapy (follow-up)</time_frame>
    <description>The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient benefit</measure>
    <time_frame>Baseline</time_frame>
    <description>The Patient Benefit Index is a standardized questionnaire measuring patients' treatment needs and treatment benefits for skin diseases. The PBI comprises two components:&#xD;
Patient Needs Questionnaire measuring the importance of different treatment goals from the patient perspective.&#xD;
Patient Benefit Questionnaire measuring the achievement of the treatment goals from the patient perspective.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient benefit</measure>
    <time_frame>Week 7 of chemotherapy (washout)</time_frame>
    <description>The Patient Benefit Index is a standardized questionnaire measuring patients' treatment needs and treatment benefits for skin diseases. The PBI comprises two components:&#xD;
Patient Needs Questionnaire measuring the importance of different treatment goals from the patient perspective.&#xD;
Patient Benefit Questionnaire measuring the achievement of the treatment goals from the patient perspective.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient benefit</measure>
    <time_frame>Week 13 of chemotherapy</time_frame>
    <description>The Patient Benefit Index is a standardized questionnaire measuring patients' treatment needs and treatment benefits for skin diseases. The PBI comprises two components:&#xD;
Patient Needs Questionnaire measuring the importance of different treatment goals from the patient perspective.&#xD;
Patient Benefit Questionnaire measuring the achievement of the treatment goals from the patient perspective.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient benefit</measure>
    <time_frame>2 weeks post-chemotherapy (follow-up)</time_frame>
    <description>The Patient Benefit Index is a standardized questionnaire measuring patients' treatment needs and treatment benefits for skin diseases. The PBI comprises two components:&#xD;
Patient Needs Questionnaire measuring the importance of different treatment goals from the patient perspective.&#xD;
Patient Benefit Questionnaire measuring the achievement of the treatment goals from the patient perspective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Baseline</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 1 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 2 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 3 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 4 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 5 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 6 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 7 of chemotherapy (washout)</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 8 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 9 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 10 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 11 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 12 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>Week 13 of chemotherapy</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient subjective evaluation of skin reactions</measure>
    <time_frame>2 weeks post-chemotherapy (follow-up)</time_frame>
    <description>The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - DLQI</measure>
    <time_frame>Baseline</time_frame>
    <description>Dermatology Life Quality Index (DLQI) is a questionnaire with 10 items and is used to measure QoL of dermatological patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - DLQI</measure>
    <time_frame>Week 7 of chemotherapy (washout)</time_frame>
    <description>Dermatology Life Quality Index (DLQI) is a questionnaire with 10 items and is used to measure QoL of dermatological patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - DLQI</measure>
    <time_frame>Week 13 of chemotherapy</time_frame>
    <description>Dermatology Life Quality Index (DLQI) is a questionnaire with 10 items and is used to measure QoL of dermatological patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - DLQI</measure>
    <time_frame>2 weeks post-chemotherapy (follow-up)</time_frame>
    <description>Dermatology Life Quality Index (DLQI) is a questionnaire with 10 items and is used to measure QoL of dermatological patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - Skindex-29</measure>
    <time_frame>baseline</time_frame>
    <description>The skindex-29 is a validated instrument to measures patients' QoL specifically correlated with skin conditions. It has 3 scales addressing emotions (10 items), symptoms (7 items) and functioning (12 items).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - Skindex-29</measure>
    <time_frame>Week 7 of chemotherapy (washout)</time_frame>
    <description>The skindex-29 is a validated instrument to measures patients' QoL specifically correlated with skin conditions. It has 3 scales addressing emotions (10 items), symptoms (7 items) and functioning (12 items).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - Skindex-29</measure>
    <time_frame>Week 13 of chemotherapy</time_frame>
    <description>The skindex-29 is a validated instrument to measures patients' QoL specifically correlated with skin conditions. It has 3 scales addressing emotions (10 items), symptoms (7 items) and functioning (12 items).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - Skindex-29</measure>
    <time_frame>2 weeks post-chemotherapy (follow-up)</time_frame>
    <description>The skindex-29 is a validated instrument to measures patients' QoL specifically correlated with skin conditions. It has 3 scales addressing emotions (10 items), symptoms (7 items) and functioning (12 items).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction with the therapeutic intervention</measure>
    <time_frame>Week 7 of chemotherapy</time_frame>
    <description>The patients will be asked to evaluate the general pleasantness and soothing effect of the skin care products by using a numerical rating scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction with the therapeutic intervention</measure>
    <time_frame>Week 13 of chemotherapy</time_frame>
    <description>The patients will be asked to evaluate the general pleasantness and soothing effect of the skin care products by using a numerical rating scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction with the therapeutic intervention</measure>
    <time_frame>2 weeks post-chemotherapy (follow-up)</time_frame>
    <description>The patients will be asked to evaluate the general pleasantness and soothing effect of the skin care products by using a numerical rating scale.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>General patient-, disease-, and treatment-related information</measure>
    <time_frame>Baseline</time_frame>
    <description>General and medical information will be collected through a short patient questionnaire in order to assess intrinsic risk factors (i.e., gender, age, smoking history, work habits, physical activity, skin condition, alcohol use, and medication use). Furthermore, information about disease- and treatment-related risk factors will be collected through medical records (e.g., tumor type and stage, tumor site, treatment type, radiotherapy regimen).</description>
  </other_outcome>
  <other_outcome>
    <measure>General patient-, disease-, and treatment-related information</measure>
    <time_frame>Week 13 of chemotherapy</time_frame>
    <description>General and medical information will be collected through a short patient questionnaire in order to assess intrinsic risk factors (i.e., gender, age, smoking history, work habits, physical activity, skin condition, alcohol use, and medication use). Furthermore, information about disease- and treatment-related risk factors will be collected through medical records (e.g., tumor type and stage, tumor site, treatment type, radiotherapy regimen).</description>
  </other_outcome>
  <other_outcome>
    <measure>General patient-, disease-, and treatment-related information</measure>
    <time_frame>2 weeks post-chemotherapy</time_frame>
    <description>General and medical information will be collected through a short patient questionnaire in order to assess intrinsic risk factors (i.e., gender, age, smoking history, work habits, physical activity, skin condition, alcohol use, and medication use). Furthermore, information about disease- and treatment-related risk factors will be collected through medical records (e.g., tumor type and stage, tumor site, treatment type, radiotherapy regimen).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Skin Toxicity</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will first receive the experimental emollient during 6 weeks, followed by no treatment for 6 weeks. In between there will be a washout period of 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will first receive no treatment during 6 weeks, followed by the experimental emollient for 6 weeks. In between there will be a washout period of 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self-prepared emollient</intervention_name>
    <description>The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with cancer of any type&#xD;
&#xD;
          -  Undergoing chemotherapy at the Jessa Hospital (Hasselt, BE)&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Able to comply to the study protocol&#xD;
&#xD;
          -  Able to sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing skin rash, ulceration, skin infections or open wounds&#xD;
&#xD;
          -  Severe psychological disorder or dementia&#xD;
&#xD;
          -  Any condition that is unstable or could affect the safety of the patient and their&#xD;
             compliance in the study as judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeroen Mebis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jessa Ziekenhuis VZW</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeroen Mebis, MD, PhD</last_name>
    <phone>+32 11 33 72 21</phone>
    <email>Jeroen.mebis@jessazh.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jolien Robijns, PhD</last_name>
    <phone>+32 11 33 72 29</phone>
    <email>jolien.robijns@uhasselt.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jessa Ziekenhuis VZW</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Mebis, MD, PhD</last_name>
      <phone>+32 11 33 72 21</phone>
      <email>Jeroen.mebis@jessazh.be</email>
    </contact>
    <investigator>
      <last_name>Jolien Robijns, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>skin</keyword>
  <keyword>emollient</keyword>
  <keyword>oncology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emollients</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

